In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
Doctors claimed it is the first time that cases of gallbladder gangrene have been reported after recovery from COVID-19 infection.
As the Omicron strain spreads across the globe and questions on vaccine inequity dominate discussions, scientists are still scrambling to learn more about emerging variants of the deadly virus that has claimed millions of lives and crippled economies.
The Hyderabad-based manufacturer uses a proprietary adjuvant Algel-IMDG, which has now proven to be a safe and effective adjuvant, especially to stimulate memory T cell responses.
Among states and union territories, the analysis by Lahariya showed that Uttar Pradesh missed the highest number of cases. With every case reported in that state, 98 cases were missed or remained undetected.
Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.
'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'
India is expecting 156 million doses of the vaccine from August to September, reports Ruchika Chitravanshi.
Bharat Biotech applied to the Drugs Controller General of India (DCGI) seeking permission for conducting phase 1 and phase 2 clinical trials of the intranasal vaccine following which the subject expert committee of the CDSCO on Tuesday deliberated on the application and recommended granting permission for phase 1 trial.
The study, published in the Journal of Pediatrics, also challenges the current hypothesis that because children have lower numbers of immune receptors for SARS-CoV2, the virus that causes COVID-19, this makes them less likely to become infected or seriously ill.
'Working in collaboration is beneficial and more rewarding in the long run.' 'Competition may bring personal glory, but is very short lasting.' 'Work with people who are interested in working with you instead of competing with you.'
Novak Djokovic blamed "human error" on Wednesday for a mistake in his Australian immigration paperwork and apologised for breaking isolation for a photoshoot when he had COVID-19 last month.
The assurance comes as India's Covid graph dips -- on Friday 1,109 new coronavirus infections were reported -- and also one case of a new Covid strain in Mumbai.
Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.
The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 3,700 lives with more than 1,25,000 cases in the country.
Gennova has also got permission for phase-2 and 3 clinical trials for its lyophilised mRNA vaccine for injection from the subject expert committee advising the Central Drugs Standards Control Organisation, reports Sohini Das.
The reduced severity of the Omicron variant is good news for now, but it is the result of an 'evolutionary mistake' and does not indicate that the virus which causes COVID-19 is becoming less virulent, a leading Indian-origin scientist from the University of Cambridge warned on Thursday.
The efficacy of the vaccine, developed by the Gamalaya Centre, was demonstrated on the basis of a first interim analysis obtained 21 days after the first injection.
Neutralising antibodies are important in potentially protecting a person from re-infection of the same virus.
The reduced severity of Omicron is good news for now, but it is the result of an "evolutionary mistake" as Covid-19 is transmitting very efficiently and there is no reason for it to become milder, indicating that the next variant could be more virulent, a leading Indian-origin scientist from the University of Cambridge has warned.
'In the likelihood that Omicron is circulating, you have a much greater chance of getting infected now, than you did during the Age of Delta.'
This year, India's Prime Minister Narendra Modi, Bollywood actor Ayushmann Khurrana, the 'dadi from Shaheen Bhagh' Bilkis, Alphabet and Google CEO Sundar Pichai and Professor Ravindra Gupta are among TIME's 100 most influential people of 2020.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
The volunteer said he had also volunteered 10 years ago for clinical trials for a vaccine against the H1N1 (swine flu) virus.
The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.
'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'
'There is no emergency of a third wave that we are rushing for booster doses.'
Union Health Minister Harsh Vardhan on Friday said the COVID-19 vaccination drive will be extended in the coming days and asserted that there should not be any misconceptions about the two Indian vaccines being administered in the country.
'There is indeed a link between BCG vaccination and resistance to COVID-19.'
The Omicron variant carries 'concerning' mutations that may make it more transmissible and allow it to evade immunity, scientists said on Monday, stressing that the one certainty in the uncertainty of the many things unknown is this -- COVID is not a short-term crisis and vaccines are still a critical tool.
The study describes a new blood test which pinpoints the immune system molecules called antibodies in infected individuals that specifically target a unique piece of the novel coronavirus SARS-CoV-2's spike protein.
The Centre has also contacted five domestic and three multinational vaccine makers to understand how soon a candidate vaccine against Covid-19 will be ready.
'You have sufficient protection if you take the second dose of the Covishield vaccine at 12 weeks, because this vaccine works in a way where it provides protection in the first dose.'
A thirst for knowledge is essential for survival in this knowledge intensive field, but also important are skill sets like team work, multi-tasking and awareness of intellectual property rights.
'There is no data to show this virus is more deadlier.'
As the global debate on booster shots gathers momentum, several scientists in New Delhi said the priority must be to ensure that more people are inoculated with at least their first jab.
The expose, which was in Chinese, said that the Chinese Communist Party was covering up the COVID-19 crisis and there was a human-to-human transmission of the virus.
The award was presented by Dr Martin Mackay, pesident Global R&D, Pfizer and Karun Rishi, president, USA-India Chamber of Commerce, at a function in Boston recently, according to a release by the chamber.
The approval comes a day after Sinopharm said its vaccine showed 79.34 per cent efficacy and a 99.52 per cent antibody-positive conversion rate in the interim results of the Phase III clinical trials.
